Amyloidosis Treatment Market Size, Share, Growth Analysis, By End-user(Hospitals, Clinics, and Research Institutions), By Treatment(Chemotherapy, Stem Cell Transplant, Symptomatic Management, and Novel Therapies), By Region - Industry Forecast 2025-2032

Amyloidosis Treatment Market size was valued at USD 4.72 billion in 2021 and is poised to grow from USD 5.46 billion in 2023 to USD 9.13 billion by 2030, at a CAGR of 7.6% during the forecast period (2023-2030).

The market for amyloidosis treatment is characterized by competition among pharmaceutical companies, biotechnology firms, and research institutions. Established amyloidosis treatment providers have led the charge in terms of the development of innovative therapies for amyloidosis by actively participating in clinical trials and research collaborations to always maintain their competitive advantage. Additionally, smaller biotech firms such as Prothena Corporation and Ionis Pharmaceuticals have made noteworthy contributions with promising drug candidates targeting amyloidosis. Moreover, academic and research institutions play a pivotal role in deepening our understanding of amyloidosis and exploring potential therapies. The competitive dynamics in this market are fueled by the urgency to provide effective treatments due to the high unmet medical need for amyloidosis. As ongoing research unveils new insights and therapeutic targets, the competitive landscape is likely to be further shaped by partnerships and acquisitions, as companies aim to strengthen their pipelines and broaden their presence in this expanding market. 'Pfizer Inc. (USA)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Alnylam Pharmaceuticals, Inc. (USA)', 'Ionis Pharmaceuticals, Inc. (USA)', 'Eidos Therapeutics, Inc. (USA)', 'Prothena Corporation plc (Ireland)', 'Akcea Therapeutics, Inc. (USA)', 'Janssen Pharmaceuticals, Inc. (USA)', 'GlaxoSmithKline plc (UK)', 'Novartis International AG (Switzerland)', 'Bristol-Myers Squibb Company (USA)', 'Sanofi S.A. (France)', 'Ionis Pharmaceuticals, Inc. (USA)', 'Oncopeptides AB (Sweden)', 'Alexion Pharmaceuticals, Inc. (USA)', 'Celgene Corporation (USA) [Acquired by Bristol-Myers Squibb]', 'Amgen Inc. (USA)', 'Caelum Biosciences (USA)', 'Spectrum Pharmaceuticals, Inc. (USA)', 'EUSA Pharma (UK)'

Increasing Prevalence of Amyloidosis: The incidence of AL amyloidosis and ATTR amyloidosis have increased across the world boosting demand for amyloidosis treatment. The growing availability of advanced diagnostic procedures and increased awareness regarding amyloidosis are also contributing to the amyloidosis treatment market growth.

Advancements in Targeted Therapies: Notable progress was witnessed in the exploration of targeted therapies for amyloidosis through research and development. Monoclonal antibodies and small molecules were actively under investigation as potential interventions to impede the production or accumulation of amyloid proteins, the defining characteristic of the disease. Numerous clinical trials were in progress to evaluate the safety and efficacy of these innovative therapies.

North America accounts for a major market share of more than 65% at present. The presence of a developed healthcare ecosystem and growing awareness regarding amyloidosis are key factors contributing to the dominant stance of North America. The United States is slated to lead amyloidosis treatment demand in North America owing to the growing availability of novel amyloidosis treatments and high investments in medical R&D activities.

Amyloidosis Treatment Market size was valued at USD 5.46 billion in 2022 and is poised to grow from USD 5.87 billion in 2023 to USD 10.56 billion by 2031, at a CAGR of 7.6% during the forecast period (2024-2031).

The amyloidosis treatment market features a competitive landscape marked by a mix of pharmaceutical companies, biotechnology firms, and research institutions. Key players such as Pfizer, Takeda Pharmaceutical, and Alnylam Pharmaceuticals have been at the forefront of developing innovative therapies for amyloidosis. These companies are actively engaged in clinical trials and research collaborations to advance treatment options. Additionally, smaller biotech companies like Prothena Corporation and Ionis Pharmaceuticals have also contributed with promising drug candidates targeting amyloidosis. Furthermore, academic and research institutions play a crucial role in advancing our understanding of amyloidosis and developing potential therapies. The competitive dynamics in this market are driven by the race to bring effective treatments to patients, given the high unmet medical need for amyloidosis. As research continues to uncover new insights and therapeutic targets, partnerships and acquisitions are likely to shape the competitive landscape further, as companies seek to bolster their pipelines and expand their footprint in this growing market. 'Pfizer Inc. (USA)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Alnylam Pharmaceuticals, Inc. (USA)', 'Ionis Pharmaceuticals, Inc. (USA)', 'Eidos Therapeutics, Inc. (USA)', 'Prothena Corporation plc (Ireland)', 'Akcea Therapeutics, Inc. (USA)', 'Janssen Pharmaceuticals, Inc. (USA)', 'GlaxoSmithKline plc (UK)', 'Novartis International AG (Switzerland)', 'Bristol-Myers Squibb Company (USA)', 'Sanofi S.A. (France)', 'Ionis Pharmaceuticals, Inc. (USA)', 'Oncopeptides AB (Sweden)', 'Alexion Pharmaceuticals, Inc. (USA)', 'Celgene Corporation (USA) [Acquired by Bristol-Myers Squibb]', 'Amgen Inc. (USA)', 'Caelum Biosciences (USA)', 'Spectrum Pharmaceuticals, Inc. (USA)', 'EUSA Pharma (UK)'

The growing prevalence of amyloidosis, including both AL amyloidosis and ATTR amyloidosis, is a significant driver of the market. As awareness and diagnostics improve, more cases are being diagnosed, leading to a larger patient pool in need of treatment.

Advancements in Targeted Therapies: Research and development efforts were focused on the development of targeted therapies for amyloidosis. Monoclonal antibodies and small molecules were being explored as potential treatments to inhibit the production or deposition of amyloid proteins, which are the hallmark of the disease. Several clinical trials were underway to assess the safety and efficacy of these novel therapies.

North America is the largest market, accounting for over 65% of the market share. This is attributed to several factors, including high awareness of the disease, developed healthcare infrastructure, increasing availability of treatment options, and strong research and development (R&D) activities. Europe is the second largest market, with a market share of around 20%. The market in this region is expected to grow at a CAGR of 7.5% during the forecast period, driven by factors such as increasing aging population, rising prevalence of amyloidosis, and growing investment in R&D. Asia Pacific is the fastest growing market, with a CAGR of 8.5% during the forecast period. This is due to factors such as growing awareness of the disease in the region, increasing disposable income, and rising government initiatives to support rare disease patients.